Document is current
Any future updates will be listed below
-
Authors
Leenay, Ryan T.
Aghazadeh, Amirali http://orcid.org/0000-0003-0223-0873
Hiatt, Joseph http://orcid.org/0000-0002-8015-9614
Tse, David
Roth, Theodore L.
Apathy, Ryan
Shifrut, Eric
Hultquist, Judd F.
Krogan, Nevan
Wu, Zhenqin http://orcid.org/0000-0002-0148-7055
Cirolia, Giana
Canaj, Hera
Leonetti, Manuel D. http://orcid.org/0000-0002-4881-405X
Marson, Alexander http://orcid.org/0000-0002-2734-5776
May, Andrew P. http://orcid.org/0000-0003-3567-3435
Zou, James http://orcid.org/0000-0001-8880-4764
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (P50 GM082250)
National Science Foundation (CRII 1657155)
- License Information
-
More Information
Article History
Received: 19 October 2018
Accepted: 27 June 2019
First Online: 29 July 2019
Competing interests
: A.M. is a co-founder of Spotlight Therapeutics. A.M. has served as an advisor to Juno Therapeutics, is a member of the scientific advisory board at PACT Pharma and an is advisor to Sonoma Biotherapeutics. The Marson laboratory has received sponsored research support from Juno Therapeutics, Epinomics, Sanofi and a gift from Gilead. A.M. and T.L.R. are co-founders of Arsenal Biosciences and T.L.R. is chief scientific officer of the company.
